Sinovac Biotech logo

SVA - Sinovac Biotech News Story

$6.47 0.0  0.0%

Last Trade - 22/02/19

Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £190.3m
Position in Universe th / 6846

Thailand urges calm after death of COVID-19 vaccine recipient

Fri 26th March, 2021 5:58am
BANGKOK, March 26 (Reuters) - Thai health officials rushed
to calm public fears on Friday after confirming a man had died
10 days after receiving a COVID-19 vaccine earlier this month.  
    The cause of death was from an abdominal aortic aneurysm
(AAA) and rupture, senior health official Sopon Mekton said,
adding the country's vaccination campaign would continue. 
    The man was inoculated on March 3 and died on March 13. 
    "I am confident this death is from the aneurysm and not
related to the vaccine," Sopon told a news conference.
    An AAA is the swelling of the main blood vessel that leads
from the heart and ruptures can be fatal. 
    The man, whose age was not disclosed, had a pre-existing
health condition and had undergone surgery in January, said
health official Tawee Chotpitayasunond, describing it as "a time
bomb in the body".
    Health Minster Anutin Charnvirakul urged the public to take
    So far, Thailand has administered about 136,000 doses of
coronavirus vaccines, mostly using those of China's Sinovac
Biotech  SVO.O  but AstraZeneca  AZN.L  vaccines have also been
    Prime Minister Prayuth Chan-ocha was the first in Thailand
to receive an AstraZeneca shot on March 16, which was delayed by
several days after reports in Europe of blood clots among some
    Those inoculated in Thailand so far have been frontline
medical workers or groups seen as at risk due to potential
exposure to the virus, or their age and pre-existing health
    Thailand has reported 28,577 coronavirus infections and 92

 (Reporting by Chayut Setboonsarng and Panarat Thepgumpanat;
Editing by Martin Petty)
 ((, Twitter: @ChayutSet;
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.